WS/T 485-2016Technical regulations for application of antimalarials (English PDF)

Foreword

This standard was drafted in accordance with the rules given in GB/T 1.1-2009.

This standard was drafted. Institute of Parasitic Diseases in Jiangsu Province, China Center for Disease Control and Prevention parasites control, Guangzhou University of Chinese Medicine, Zhongshan Medical College, Zhongshan University.

Drafters of this standard. Gao Qi, Tang Linhua, Fu Linchun, Yu Xinbing, Guan Yayi, Zhou Shui-sen, Xia Zhi Gui, Cao Jun, Zhou Huayun.

Anti-malarial drug use specification

1 Scope

This standard specifies the choice and use of anti-malarial drugs.

This standard applies to medical institutions and disease prevention and control agencies for the prevention and treatment of malaria.

2 Normative references

The following documents for the application of this document is essential. For dated references, only the dated version applies to this article Pieces. For undated references, the latest edition (including all amendments) applies to this document.

WS 259 Malaria diagnostic criteria

3 Terms and definitions

WS 259 and defined by the following terms and definitions apply to this document.

Relapse

Plasmodium vivax or Plasmodium falciparum in the blood of patients with Plasmodium vivax was cleared for several weeks or months after development by P. falciparum dormant in the liver Schizonts, the release of merozoites into the blood for Rift multiplication, re-emergence of clinical symptoms and signs of malaria.

Rest period radical anti-relapsetreatment in endemic areas of malaria, primaquine treatment was used prior to the pre-season season for patients who had had vivax malaria or oval malaria within a year, clearing the possibility of Intrahepatic malaria parasite to prevent recurrence.

Artemisinin-based combination of therapies based on artemisinin; ACTs Compound or combination regimens of artemisinin or its derivatives with one or more other anti-malarial drugs. Abbreviated artemisinin class Compound.

4 Antimalarial drug use principles

The use of anti-malarial drugs should follow the principles of safety, efficiency, reasonableness and standardization. Should be based on the parasite species and its antimalarial drug sensitivity and Patients with clinical symptoms and signs of a reasonable choice of drugs, and should strictly control the dose, treatment and route of administration to ensure that the treatment and prevention effect and Delay the emergence of drug resistance.

5 Anti-malarial choice